CNSP Stock — CNS Pharmaceuticals, Inc.: Metrics

Market overview

2 metrics

Share price

$6.01

Market cap

$8.78M

Price action

19 metrics

Price change (1W)

+1.6%

Price change (30D)

+1.8%

Price change (3M)

+19.8%

Price change (6M)

+93.8%

Price change (YTD)

+12.2%

Price change (1Y)

-5.0%

Trailing year

Price change (5Y)

—

52-week high

$10.57

52-week low

$2.13

Change from 52-week high

-44.3%

Change from 52-week low

+176.6%

Annualized volatility

254.8%

Beta

0.1

RSI (14D)

56.6

Price vs SMA 50

+12.8%

Price vs SMA 200

+21.6%

Avg volume (3M)

11,223

Relative volume

0.2

Average dollar volume

$56,810

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

1.46M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

0.5

reciprocal yield 215.8%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-198.0%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2020-03-12

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$16.92M

Net income (TTM)

−$16.70M

Trailing 12 months

Diluted EPS (TTM)

$-18.08

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$14.31

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+1,747.5%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-91.8%

Return on assets

-76.1%

Debt / equity

—

Current ratio

5.9

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

5.9

Interest coverage

-1,117.8

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$19.98M

Total assets

$21.94M

Total debt

$449,874

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$13.41M

Capital expenditures (TTM)

—

R&D (TTM)

$10.11M

SG&A (TTM)

—

Stock compensation (TTM)

$107,916

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

11

13F filer change QoQ

-1

Institutional ownership

19.2%

Short interest

3 metrics

Short interest

0.9%

Latest settlement · 2.9 days to cover

Days to cover

2.9d

Short-squeeze score

65 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

CNSP · CNS Pharmaceuticals, Inc.

CNSP metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search